Login to Your Account

Merck Paying $350M In Stock For Acquisition Of NovaCardia

By Jim Shrine

Thursday, July 26, 2007
NovaCardia Inc., which has a Phase III product for congestive heart failure, is being acquired by Merck & Co. Inc. for $350 million in stock. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription